Page last updated: 2024-12-06

tucaresol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tucaresol: causes a dose-dependent left-shift of the oxygen saturation curve of hemoglobin S by stabilization of its oxy-(R)-conformation; an anti-sickling agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID55223
CHEMBL ID2104482
SCHEMBL ID600942
MeSH IDM0165817

Synonyms (36)

Synonym
tucaresol
4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid
bw a589c
benzoic acid, 4-((2-formyl-3-hydroxyphenoxy)methyl)-
unii-jh368g5b9m
tucaresol [inn:ban]
bw-589c
jh368g5b9m ,
bw 589c
alpha-(2-formyl-3-hydroxyphenoxy)-p-toluic acid
589c80
589c
84290-27-7
589-c
CHEMBL2104482
benzoic acid, 4-[(2-formyl-3-hydroxyphenoxy)methyl]-
4-[(2-formyl-3-hydroxy-phenoxy)methyl]benzoic acid
bwa 589c
SCHEMBL600942
tucaresol [mart.]
.alpha.-(2-formyl-3-hydroxyphenoxy)-p-toluic acid
tucaresol [inn]
XEDONBRPTABQFB-UHFFFAOYSA-N
4-(2-formyl-3-hydroxyphenoxymethyl) benzoic acid
4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid
DTXSID70233247
F9994-5209
AKOS027327314
DB13027
4-((2-formyl-3-hydroxyphenoxy)methyl)benzoic acid
589c; 589c80; bwa 589c
E78089
Q27281503
BS-50680
4-[(2-formyl-3-hydroxyphenoxy)methyl]-benzoic acid
4-((2-formyl-3-hydroxyphenoxy)methyl)benzoicacid

Research Excerpts

Overview

Tucaresol is an orally administered antisickling agent. It increases the oxygen affinity of haemoglobin.

ExcerptReferenceRelevance
"1. Tucaresol is an orally administered antisickling agent which increases the oxygen affinity of haemoglobin. "( Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.
Mercer, AJ; Posner, J; Rolan, PE; Wootton, R, 1995
)
1.18

Pharmacokinetics

ExcerptReferenceRelevance
" Mean Cmax values in plasma and erythrocytes were 81."( Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.
Mercer, AJ; Posner, J; Rolan, PE; Wootton, R, 1995
)
0.56
"There were no significant differences in standard pharmacokinetic parameters between the two occasions but the rate of tucaresol absorption was faster after food intake."( Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers.
Layton, G; Peck, RW; Posner, J; Wiggs, R; Wootton, R, 1998
)
0.76

Bioavailability

ExcerptReferenceRelevance
" Tucaresol, which is orally bioavailable and systemically active, enhances CD4 Th-cell and CD8 cytotoxic T-cell responses in vivo and selectively favours a Th1-type profile of cytokine production."( Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential.
Chen, H; Rhodes, J, 1996
)
1.2

Dosage Studied

The utility of tucaresol in the management of sickle cell disease will depend on the identification of a dosing regimen with a lower incidence of drug allergy. The acute increase in oxygen affinity is physiologically well-tolerated.

ExcerptRelevanceReference
" The acute increase in oxygen affinity with tucaresol is physiologically well-tolerated, but the utility of tucaresol in the management of sickle cell disease will depend on the identification of a dosing regimen with a lower incidence of drug allergy."( Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.
Mercer, AJ; Posner, J; Rolan, PE; Wootton, R, 1995
)
0.82
" Due to concerns over the sharp rise in haematocrit in one patient, subsequent cohorts received 300 mg tucaresol daily throughout the dosing period."( Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia.
Arya, R; Bellingham, AJ; Posner, J; Rolan, PE; Wootton, R, 1996
)
1.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1678657Immuno-adjuvant activity in E2deltaTM3-immunized BALB/cj mouse assessed as neutralization of HCV H77 genotype 1a pseudotyped virus particle with pooled immune sera at 1 ug/ml2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model.
AID1755546Clearance in human at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755548Half life in human plasma at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755540Cmax in human erythrocytes at 37 mg/kg, po2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755541Cmax in human plasma at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755542Tmax in human erythrocytes at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755547Half life in human erythrocytes at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755545AUC (0 to 24 hrs) in human plasma at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755539Ratio of drug level in human erythrocytes to plasma at 20 mg/kg, iv measured over 1 hr2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755544AUC (0 to 24 hrs) in human erythrocytes at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
AID1755543Tmax in human plasma at 37 mg/kg, po by HPLC method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.85)18.7374
1990's12 (46.15)18.2507
2000's8 (30.77)29.6817
2010's3 (11.54)24.3611
2020's2 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.50 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.63 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (19.23%)5.53%
Reviews4 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (65.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]